Taysha Gene Therapies, Inc.
TSHA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001806310
In the last 90 days, Taysha Gene Therapies, Inc. insiders filed 0 open-market purchases and 1 sale; 208 institutions reported holding it in 13F filings for Q2 2026, worth $2.03B in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Taysha Gene Therapies, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 52 | 44 | −8 |
| Shares | 19.4M | 16.7M | −2.69M (−13.9%) |
| Value | $43.8M | $13.3M | −$30.5M (−69.7%) |
New holders (5)
Institutions that held Taysha Gene Therapies, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| XTX Topco Ltd | 85,167 | $67.9K | 0.01% |
| Virtu Financial LLC | 45,459 | $36.0K | 0.00% |
| Engineers Gate Manager LP | 13,650 | $10.9K | 0.00% |
| Camelot Portfolios, LLC | 11,000 | $8.77K | 0.01% |
| Simplex Trading, LLC | 10,767 | $8.00K | 0.00% |
Sold out (13)
Institutions that held Taysha Gene Therapies, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Altium Capital Management LP | 359,051 | $811.5K |
| Marshall Wace, LLP | 69,296 | $156.6K |
| Barclays PLC | 44,013 | $96.8K |
| Cubist Systematic Strategies, LLC | 40,301 | $91.1K |
| Caas Capital Management LP | 22,994 | $52.0K |
| Jump Financial, LLC | 16,917 | $38.2K |
| Maven Securities LTD | 15,000 | $33.9K |
| RBF Capital, LLC | 13,800 | $31.0K |
| Goldman Sachs Group Inc | 12,127 | $27.4K |
| Bordeaux Wealth Advisors LLC | 10,000 | $22.6K |
| Quantbot Technologies LP | 9,729 | $22.0K |
| Truvestments Capital LLC | 380 | $859 |
| Money Concepts Capital Corp | 115 | $260 |